Compare NUTX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | JANX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 975.7M |
| IPO Year | 2009 | 2021 |
| Metric | NUTX | JANX |
|---|---|---|
| Price | $191.49 | $16.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $252.50 | $47.00 |
| AVG Volume (30 Days) | 120.9K | ★ 667.0K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.93 | N/A |
| EPS | ★ 15.87 | N/A |
| Revenue | ★ $875,257,000.00 | $10,000,000.00 |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $77.21 | $12.12 |
| 52 Week High | $204.00 | $35.34 |
| Indicator | NUTX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 55.96 |
| Support Level | $146.07 | $13.13 |
| Resistance Level | $195.52 | $16.68 |
| Average True Range (ATR) | 13.84 | 0.60 |
| MACD | 3.57 | 0.02 |
| Stochastic Oscillator | 79.05 | 75.39 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.